Clinical relevance of CTC and DTC subtypes characterized by a number of established tumor biomarkers-iFISH® (such as HER2 [31], CK18, PanCKs, EpCAM, α-fetoprotein [AFP], CD133, CA19.9, Vimentin, etc.)to prognosis, metastasis, drug resistance and recurrence in large cohorts of diverse types of carcinoma patient is currently under our active investigation. This evidence concerns the gene KRT18 and neoplasm.